No Prescription |
 |
 | ||
|
Provera Amen |
|
| ||
No Prescription » Prescription Drugs 13 » Provera Amen IndicationsPROVERA is indicated for:1. diagnosis of primary and secondary amenorrhoea 2. treatment of dysfunctional (anovulatory) uterine bleeding 3. opposition of endometrial effects of oestrogen in menopausal women being treated with oestrogen (hormone replacement therapy [HRT]) 4. treatment of endometriosis Dosage and Administration:Use of combined oestrogren/progestin therapy in postmenopausal women should be limited to the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman and should be periodically evaluated Unless there is a previous diagnosis of endometriosis it is not recommended to add a progestin in a woman without an intact uterus.Diagnosis of Primary and Secondary Amenorrhoea2.5 to 10 mg per day for 5-10 days.Dysfunctional (anovulatory) Uterine Bleeding2.5 to 10 mg per day for 5 to 10 days for 2 to 3 cycles and then discontinued to see if the dysfunction has regressed. If bleeding occurs from a poorly proliferative endometrium oestrogens should be used concomitantly with PROVERA therapy.Opposition of Endometrial Effects of Oestrogen in Menopausal Women Being Treated with OestrogenFor women taking 0.625 mg of conjugated oestrogen or an equivalent daily dose of another oestrogen PROVERA can be given in one or two regimens:Continuous regimen of PROVERA: 2.5 to 5.0 mg daily. Sequential regimen of PROVERA: 5 to 10 mg daily for 10 to 14 consecutive days of a 28-day or monthly cycle. Endometriosis10 mg three times a day for 90 consecutive days beginning on the first day of the menstrual cycle. Buy Provera Amen and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About Provera Amen: Product Type: Prescription Drugs 13 Provera ( Amen Cycrin Generic Medroxyprogesterone ) Provera (Amen Cycrin Generic Medroxyprogesterone) Amen Cycrin Generic Medroxyprogesterone 100mg 30 Tablets 10mg 90(3 x 30) Tablets 10mg 30 Tablets 2.5mg 30 Tablets 2.5mg 90(3 x 30) Tablets 5mg 100 Tablets 5mg 200(2 x 100) Tablets 100mg 100 tabs 10mg 30 tabs 5mg 100 tabs Amen Cycrin Generic Medroxyprogesterone Provera
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
